Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma2016 · 3,007 citations
2. 2Molecular Analysis for Therapy Choice: NCI MATCH2014 · 180 citations
3. 3New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)2008 · 29,521 citations
4. 4The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design2020 · 229 citations
5. 5BRAF Inhibition in <i>BRAF</i> ^V600 -Mutant Gliomas: Results From the VE-BASKET Study2018 · 331 citations